Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma

Long GV, Khattak MA, Gogas HJ, Schadendorf D, Arance A, Carlino MS, Rutkowski P, Rivalland G, Ribas A, Mehnert JM, Ott PA, Dummer R, Queirolo P, Gebhardt C, Dutriaux C, Rojas C, Chen Y, Tachiki LM, Shapira-Frommer R, Bechter O, Sullivan RJ, Eggermont AMM, Ojalvo LS, Brown M, Zhang J, Grebennik DO, Fukunaga-Kalabis M, Ascierto PA, Del Vecchio M; INTerpath-001 Investigators. Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma. N Engl J Med. 2026 Nov 11. doi: 10.1056/NEJMoa2609762. Epub ahead of print. PMID: 43013837.


Related Posts